We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Leading cancer centers launch Juno Therapeutics; company gets $120mm through Series A; later adds more
24 Apr 2014
Executive Summary
The Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute joined forces to launch Juno Therapeutics Inc., a company tasked with developing T cell-based cancer immunotherapies. Arch Venture Partners and the Alaska Permanent Fund (managed by Crestline Investors) are initial investors in the start-up’s concurrent $120mm Series A round.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Vaccines
Biotechnology
Gene Therapy, Cell Therapy
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?